Maybe some were less than surprised by the gist of phase III results tallied by La Jolla Pharmaceutical Co. in the ATHOS-3 study with LJPC-501 (angiotensin II) in patients with catecholamine-resistant hypotension (CRH) associated with distributive shock, but the data hinted at an even brighter picture and Wall Street rewarded the firm handsomely, sending shares (NASDAQ:LJPC) on a ride that ended Monday at $35.12, up $15.25, or 76.8 percent.